Drug Research
Regenerons REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Regeneron Pharmaceuticals, Inc. announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19....
Drug Research
Major Pharma Companies, Including Novartis And Merck, Build Federated Learning Platform For Drug Discovery
Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and...
Drug Research
Alnylam Pharmaceuticals partners with Sharp on packaging RNA interference (RNAi) therapeutics for Europe
Alnylam Pharmaceuticals Inc., the leading RNA interference (RNAi) therapeutics company, and Sharp, part of UDG Healthcare, announced an agreement for the packaging of Alnylam’s approved RNAi therapeutic in European markets.
In accordance with this agreement, Sharp Belgium’s Hamont-Achel site will...
Drug Research
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations.
The companies will globally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting LIV-1, which is...
Drug Research
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), announced a collaboration aimed at the...
Drug Research
PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its new 5,000L production line
PharmAbcine, a biotech company focusing on the development of antibody therapeutics, announced on August 31 that it had signed a contract manufacturing organization(CMO) agreement with Binex, a leading biologics CDMO(Contract Development and Manufacturing Organization) company in Korea.
With the new...
Drug Research
Catalent and Exelixis Enter into Collaboration, License, and Exclusive Option Agreement to Develop ADC Leveraging SMARTag Bioconjugation Technology
Exelixis, Inc. and Catalent announced a partnership under which Catalent’s Redwood Bioscience subsidiary will develop multiple antibody-drug conjugates (ADCs) for Exelixis using Catalent’s proprietary SMARTag® site-specific bioconjugation technology.
Under the terms of the agreement, Catalent will use its SMARTag® bioconjugation...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read